2026-06-14T03:44:44Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/187832024-09-21T19:38:09Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16968
Repisalud
author
Rueda Domínguez, Antonio
author
Cirauqui, Beatriz
author
García Castaño, Almudena
author
Alvarez Cabellos, Ruth
author
Carral Maseda, Alberto
author
Castelo Fernández, Beatriz
author
Iglesias Rey, Leticia
author
Rubió-Casadevall, Jordi
author
Arrazubi, Virginia
author
Mesía, Ricard
2024-02-27T15:16:05Z
2024-02-27T15:16:05Z
2022-03-18
10.1007/s12094-022-02814-x
1699-3055
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
http://hdl.handle.net/10668/21108
35303267
http://hdl.handle.net/20.500.12105/18783
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
eng
Clinical Practice Guidelines
Diagnosis
Follow-up
Nasopharyngeal cancer
Treatment
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
research article